Clinical Trial

Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis

Study acronym: IRIS-sICAS
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 28, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
IRIS-sICAS is a multicenter, randomized, double-blind, placebo-controlled clinical trialis a multicenter, randomized, double-blind, placebo-controlled clinical trial, to assess the safety and efficacy of tocilizumab injection in lowering the incidence of newly diagnosis ischemic stroke and improving prognosis in symptomatic intracranial atherosclerosis patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-06.
Trial Details
NCT Number NCT06447701
Lead Sponsor Zhujiang Hospital
Collaborators: Shenzhen Second People's Hospital, Central People's Hospital of Zhanjiang, Shantou Central Hospital, Eighth Affiliated Hospital, Sun Yat-sen University, Guangzhou First People's Hospital, Peking University Shenzhen Hospital, Guangdong Provincial People's Hospital
Conditions Brain Diseases, Ischemic Stroke, Ischemia, Stroke, Cerebral Infarction, Atherosclerosis of Artery, Atheroscleroses, Intracranial
Enrollment 486 participants
Start Date 2025-10-30
Primary Completion 2025-12-31 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-28